News
Bengaluru: Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Limited, has ...
Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for ...
1h
Capital Market on MSNBiocon edges higher after biologics arm launches autoimmune treatment drug Nepexto in Australia
Nepexto will be promoted by Generic Health, BBL's local partner and a leading provider of high-quality generic prescription, ...
Biocon Biologics launches Nepexto, a biosimilar for autoimmune diseases like rheumatoid arthritis, in Australia. The drug ...
Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid ...
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...
Explore more
The shares of biopharmaceutical firm Biocon fell as much as 2.04 per cent in Tuesday's trading session, figuring among top ...
Shares of Biocon experienced a decline of 2.01% to Rs 386.70 in Tuesday's session, with the stock figuring among the top ...
When Indian biotechnology firm Biocon and the world's biggest pharma company Pfizer announced their $350-million alliance in late October, the industry took it as another biotech pharma deal--by ...
Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating ...
Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced it ...
1h
Capital Market on MSNBiocon Biologics launches biosimilar - Nepexto in Australia
Biocon Biologics (BBL), a fully integrated global biosimilars company and subsidiary of Biocon, announced today it has launched Nepexto(R), a biosimilar to the reference ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results